Israeli Legislation.com

Regulation of Research into Biological Disease Agents Law, 5769-2008

חוק הסדרת מחקרים במחוללי מחלות ביולוגיים, תשס"ט-2008

Published: 2008-11-12Consolidated Hebrew text as of 2020-12-22 · Last amended 2016-06-23✓ Amendment status checked against the Knesset legislation record on 2026-11-10
Premium
Unofficial English translation — for reference only. It may contain errors or omissions and cannot be relied on as a legal text. Only the Hebrew text published in Reshumot is legally binding.More

This English text was translated from the official Hebrew using a range of translation tools, and it undergoes ongoing checks and updates. It is not a certified translation.

Despite these checks, it may contain errors, omissions, or imprecise renderings of legal terminology and cross-references, and it may not yet reflect the latest amendments. It cannot be relied upon as a legal text.

The Hebrew text as published in Reshumot (ספר החוקים) and on the Knesset website is the sole authoritative and legally binding version. In any discrepancy, the Hebrew text prevails.

This translation is provided for informational purposes only and does not constitute legal advice. For use in legal proceedings, request a certified Expert Legal Opinion.

Chapter V: Supervision

Authorisation of Inspectors§

18.

The Director may authorise, from among the employees of his Ministry, an inspector with powers under this Law, provided that all of the following conditions are satisfied in respect of him:

(1)the Israel Police has notified, no later than three months from the date of receipt of the employee's particulars, that it does not object to his appointment on grounds of public safety, including by reason of his criminal record;
(2)he has received appropriate training, as the Minister has directed;
(3)he meets additional eligibility conditions, as the Minister has directed.

Supervision§

19.

For the purpose of supervising the implementation of the provisions under this Law, an inspector may:

(1)enter an institution, after having identified himself; however, an inspector shall not enter a place used solely as a residence except pursuant to an Order of a court;
(2)require a person concerned to provide him with any information or document capable of ensuring or facilitating the implementation of this Law; in this paragraph, "document" – includes a printout as defined in the Computers Law, 5755-1995;
(3)carry out measurements and take samples of disease agents or of other materials; an inspector shall also be entitled to deliver the measurements and samples to a laboratory, to keep them or to deal with them in another manner; the samples shall be delivered to the inspector without charge;
(4)seize disease agents or other materials for the purpose of their destruction and also to destroy them as necessary, if a concern has arisen that the disease agents or those materials, held at the institution, endanger state security or public safety, health or welfare.

Right to be Heard§

20.

Notwithstanding the provisions of section 19, an inspector shall not give a direction as referred to therein to seize or destroy disease agents or other materials except after having given the institution or the researcher, as the case may be, an opportunity to present their arguments; however, if the inspector finds that delaying the giving of the direction is liable to endanger state security or public safety, health or welfare, he may give it immediately, provided that he gives the institution or the researcher, as the case may be, the opportunity to present their arguments at the earliest opportunity thereafter.

Chapter VI: Penalties

Penalties§

21.
(a)One who possesses disease agents or conducts research therein in contravention of the provisions of section 2(a) is liable to imprisonment of three years or a fine of three times the fine referred to in section 61(a)(3) of the Penal Law.
(b)One who possesses disease agents or conducts research therein without approval, in contravention of the provisions of section 2(b) or in contravention of the provisions pursuant to section 2(c)(2) or 3b), is liable to imprisonment of six months or half the fine referred to in section 61(a)(3) of the Penal Law.
(c)One who conducts research in contravention of the provisions of section 3(a) is liable to imprisonment of four years.

Liability of an Office Holder in a Corporation§

22.
(a)An office holder in a corporation is obliged to supervise and do everything possible to prevent offences under section 21 by the corporation or by any of its employees; one who contravenes this provision is liable to a fine as referred to in section 61(a)(4) of the Penal Law; for the purposes of this section, "office holder" – an active director in a corporation, a partner, excluding a limited partner, or an officer responsible on behalf of the corporation for the field in which the offence was committed.
(b)Where an offence under section 21 has been committed by a corporation or by any of its employees, it is presumed that the office holder in the corporation has breached his duty under subsection (a), unless he proves that he did everything possible to fulfil his duty.

Chapter VII: General Provisions

Maintenance of Confidentiality§

23.

A person performing a function by virtue of this Law shall not disclose any information or the contents of any document that came to his knowledge by virtue of his function, except in accordance with law.

Amendment of the Schedule§

24.

The Minister shall amend the Schedule from time to time, with the approval of the Science and Technology Committee of the Knesset.

Implementation and Regulations§

25.

The Minister is responsible for the implementation of this Law, and shall prescribe provisions in all matters relating to its implementation, including with respect to the manner of submitting applications for research and the granting of approvals, and after consultation with the Minister of Defence – with respect to conditions for the recognition of an institution and methods of supervision and control.

Limitation on Application to the Security Establishment§

26.

The provisions of this Law shall not apply to the security establishment; however, the possession of disease agents and the conduct of research therein shall be carried out in accordance with guidelines to be issued –

(1)in the subsidiary units of the Prime Minister's Office or in an institution approved by the Prime Minister – by the Director General of the Prime Minister's Office;
(2)in the Ministry of Defence, its subsidiary units or in an institution approved by the Minister of Defence – by the Director General of the Ministry of Defence;
(3)in the Israel Defence Forces – in accordance with army orders as defined in the Military Justice Law, 5715-1955.

Commencement and Transitional Provision§

27.
(a)The commencement of this Law, except for section 4, Chapter III and sections 12 and 13, shall be nine months from the day of its publication (hereinafter – the commencement day).
(b)The commencement of section 4, Chapter III and sections 12 and 13 shall be three months from the day of publication of this Law.
(c)No person shall be prosecuted for an offence committed under sections 21 or 22 during the period from the commencement day until the end of six months from the commencement day.

Schedule (Section 1)

The definition "disease agents"

Abrin;

Bacillus anthracis;

Botulinum neurotoxins;

Botulinum neurotoxin producing species of Clostridium;

Brucella abortus;

Brucella melitenis;

Brucella suis;

Burkolderia mallei (glanders);

Burkholderia pseudomallei (melioidosis);

Camel pox virus;

Central European Tick-borne encephalitis;

Ceropithecine herpesvirus 1 (Herpes B virus);

Chikungunya virus;

Chlamydophila psittaci;

Clostridium perfingens epsilon toxin;

Coccidioides immitis;

Coccidoides psadiasii;

Reconstructed replication competent forms of the 1918 pandemic influenza virus containing any portion of the coding regions of all eight gene segments (Reconstructed 1918 influenza virus);

Conotoxins;

Cowpox;

Coxiella burnetii;

Crimean-Congo haemorrhagic fever virus;

Cryptosporidium parvum;

Dengue virus;

Diacetoxyscirpenol;

Eastern Equine Encephalitis virus;

Ebola virus;

Escherichia coli 0157: H7;

Far Eastern tick-borne encephalitis;

Flexal;

Fransicella tularensis;

Guana rito;

Hendra virus;

Influenza virus (highly pathogenic): H5N1, H7N1, H7N3, H10N8, H9N2, H7N7, H5N6;

Japanese encephalitis virus;

Junin;

Kyasanur Forest disease;

Lassa fever virus;

Machupo;

Marburg virus;

Menangele virus;

MERS corona virus (Middle East respiratory syndrome);

Monkeypox virus;

Nipah virus;

Omsk Haemorrhagic Fever;

Ricin;

Rickettsia prowazekii;

Rickettsia rickettsii;

Rift Valley fever virus;

Russian Spring and Summer encephalitis;

Sabia;

SARS corona virus (Severe acute respiratory syndrome);

SARS Corona virus 2 (Severe acute respiratory syndrome coronavirus; SARS-CoV-2),

also known as Novel coronavirus 2019–(nCov-2019);

Saxitoxin;

Shiga-like ribosome inactivating proteins;

Shigatoxin;

Staphylococcal enterotoxins;

T-2 toxin Venezuelan Equine Encephalitis virus;

Tetrodotoxin;

Variola major virus (Smallpox);

Variola minor virus (Alastrim);

Venezuelan equine encephalitis;

Vibrio cholera (O1, O139);

Western Equine Encephalitis;

Yellow fever virus;

Yersina pestis;

Zika virus;

except for preparations registered in the pharmaceutical register maintained pursuant to section 47a of the Pharmacists Ordinance [New Version], 5741-1981.

Ehud Olmert Yaakov Ben Yizri

Prime Minister Minister of Health

Shimon Peres Dalia Itzik

President of the State Speaker of the Knesset

Page 2 of 2

Read the entire law on one page — continuous text, no page breaks, plus formal citations.